Teva gets tentative FDA nod to market generic Gemzar

May 8 (Reuters) - Teva Pharmaceutical Industries Ltd. (TEVA.O) said it got tentative regulatory approval to market its generic version of Eli Lilly and Co.'s (LLY.N) cancer treatment Gemzar for injection.

Teva is facing a patent suit on this product and a final approval is expected upon the earlier of a favorable decision in the case or expiry of the mandatory stay of approval in July 2008, the world's largest generic drugmaker said in a statement.

(Reporting by Supantha Mukherjee in Bangalore)

((Editing by Gopakumar Warrier;Reuters Messaging: supantha.mukherjee.reuters.com@reuters.net; within U.S.+1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: TEVA FDA/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS0298